KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $5.2 million.

  • Sarepta Therapeutics' Gains from Investment Securities rose 193.60% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 82.60%. This contributed to the annual value of $8.9 million for FY2024, which is 7.29% down from last year.
  • Sarepta Therapeutics' Gains from Investment Securities amounted to $5.2 million in Q3 2025, which was up 213.03% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Gains from Investment Securities ranged from a high of $36.8 million in Q4 2024 and a low of -$5.5 million during Q3 2024.
  • Its 3-year average for Gains from Investment Securities is $4.2 million, with a median of $1.1 million in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 35,906.49% in 2022, then slumped by 477.44% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Gains from Investment Securities stood at $77,000 in 2021, then surged by 35,906.49% to $27.7 million in 2022, then plummeted by 98.71% to $357,000 in 2023, then soared by 10,205.60% to $36.8 million in 2024, then surged by 193.60% to $5.2 million in 2025.
  • Its Gains from Investment Securities stands at $5.2 million for Q3 2025, versus -$4.6 million for Q2 2025 and $5.2 million for Q1 2025.